

Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV₁ Reversibility

Poster No. 080

Yancey SW¹, Corren J², Price RG³, Castro M⁴

¹Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA; ²David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ³Biostatistics, GSK, Stevenage, Hertfordshire, UK; ⁴University of Kansas School of Medicine, Kansas City, KS, USA

Aims


Mepolizumab has been shown to reduce the rate of clinically significant exacerbations, as well as improve asthma control compared with placebo in patients with severe eosinophilic asthma.¹⁻⁴

Previous studies show that baseline blood eosinophil count is predictive of response to mepolizumab.^{1,2,5,6}

Separately, supervised cluster analysis of the DREAM study¹ suggested that airway reversibility may be associated with improved response to mepolizumab.⁷

The aim of this post hoc analysis of the DREAM study was to evaluate the efficacy of mepolizumab in patients with severe eosinophilic asthma over a 52-week period according to baseline blood eosinophil count and forced expiratory volume in 1 second (FEV₁) reversibility.

Methods




All mepolizumab doses were combined for this analysis. *Patients in the ITT population with baseline blood eosinophil count and reversibility data were analyzed; †albuterol/salbutamol; ‡exacerbations were defined as worsening of asthma requiring use of OCS or systemic corticosteroids for ≥3 days and/or hospitalization and/or an ER visit. For patients receiving maintenance OCS, an exacerbation requiring OCS was defined as the use of oral/systemic corticosteroids at least double the existing maintenance dose for ≥3 days. ER, emergency room; FEV₁, forced expiratory volume in 1 second; ITT, intent-to-treat; IV, intravenous; OCS, oral corticosteroids; SoC, standard of care

Results

Patient population at baseline	Reversible				Non-reversible			
	<150 cells/μL	≥150 cells/μL	<300 cells/μL	≥300 cells/μL	<150 cells/μL	≥150 cells/μL	<300 cells/μL	≥300 cells/μL
Age, years	50 (11)	48 (11)	49 (11)	47 (12)	52 (9)	49 (12)	50 (11)	50 (11)
Female, n (%)	61 (60)	219 (66)	138 (63)	142 (66)	28 (64)	70 (56)	53 (59)	45 (56)
Ethnicity, n (%)								
Hispanic or Latino	13 (13)	30 (9)	23 (11)	20 (9)	5 (11)	12 (10)	11 (12)	6 (8)
Not Hispanic or Latino	89 (87)	302 (91)	195 (89)	196 (91)	39 (89)	114 (90)	79 (88)	74 (93)
Asthma duration, years	18 (15)	18 (14)	18 (14)	18 (14)	20 (15)	22 (15)	21 (15)	21 (15)
Exacerbations in previous year	3.4 (2.9)	3.8 (3.6)	3.5 (3.5)	3.8 (3.3)	3.7 (1.9)	3.3 (2.1)	3.5 (2.2)	3.4 (1.9)
Smoking status, n (%)								
Never smoked	76 (75)	269 (81)	165 (76)	180 (83)	30 (68)	96 (76)	62 (69)	64 (80)
Former smoker	26 (25)	63 (19)	53 (24)	36 (17)	14 (32)	30 (24)	28 (31)	16 (20)
On maintenance OCS therapy, n (%)	28 (27)	102 (31)	65 (30)	65 (30)	20 (45)	36 (29)	31 (34)	25 (31)
Pre-bronchodilator FEV ₁ , L	1.95 (0.71)	1.89 (0.62)	1.93 (0.68)	1.88 (0.60)	1.74 (0.65)	1.84 (0.73)	1.84 (0.74)	1.80 (0.67)
Pre-bronchodilator FEV ₁ , % predicted	61.0 (15.2)	60.1 (15.2)	60.9 (15.0)	59.7 (15.4)	58.4 (15.5)	57.8 (18.6)	58.9 (17.7)	56.9 (18.0)
FEV ₁ reversibility, %	29.7 (20.24)	30.3 (23.18)	30.9 (20.85)	29.4 (24.08)	11.6 (9.77)	14.0 (12.85)	12.5 (13.31)	14.4 (10.69)
ACQ-6 score	2.5 (1.0)	2.4 (1.1)	2.4 (1.0)	2.5 (1.2)	2.1 (1.0)	2.0 (1.1)	2.1 (1.1)	2.1 (1.1)
Blood eosinophil count, cells/μL, geometric mean (SD logs)	70 (0.75)	390 (0.60)	120 (0.78)	560 (0.44)	60 (0.99)	390 (0.64)	110 (0.95)	560 (0.52)
FeNO, ppb, geometric mean (SD logs)	25.1 (0.86)	35.7 (0.75)	27.4 (0.80)	39.5 (0.73)	24.5 (0.78)	30.1 (0.80)	25.4 (0.78)	32.6 (0.80)

Values are presented as mean (SD) unless otherwise stated. ACQ, Asthma Control Questionnaire; FeNO, fractional exhaled nitric oxide; ppb, parts per billion; SD, standard deviation


Patient subgroups



Conclusions


- Previous analyses have shown an association between exacerbation reduction with mepolizumab and higher baseline eosinophil counts.
- This exploratory analysis reaffirms that baseline blood eosinophil counts remain the most useful predictor of improved response to mepolizumab treatment in terms of exacerbations.
- Based on this analysis the role of airway reversibility in predicting response to mepolizumab treatment is still unclear and may not have additional impact, although the low numbers of patients receiving placebo in this analysis (particularly among non-reversible patients) is a limitation.
 - In cases where patients performed worse with mepolizumab compared with placebo, this was driven mainly by a relatively small number of patients with baseline blood eosinophils <150 cells/μL (ie, outside the specific population for which mepolizumab is approved).
- Furthermore, it is possible that some patients classified as non-reversible may also have had airflow variability or hyper-responsiveness.

Reductions in the rate of clinically significant exacerbations over 52 weeks favored mepolizumab versus placebo in those with higher baseline blood eosinophil count, and this effect was more pronounced in those who were not reversible



*Ratio of exacerbation rates among patients receiving mepolizumab to exacerbation rates among patients receiving placebo. CI, confidence interval

There were fewer clinically significant exacerbations over 52 weeks with mepolizumab versus placebo in those with higher baseline blood eosinophil count, and this effect was increased in those without reversibility



References

- Pavord ID, et al. *Lancet* 2012;380:651–9.
- Ortega HG, et al. *N Engl J Med* 2014;371:1198–207.
- Chupp GL, et al. *Lancet Respir Med* 2017;5:390–400.

References

- Bel EH, et al. *N Engl J Med* 2014;371:1189–97.
- Ortega HG, et al. *Lancet Respir Med* 2016;4:549–56.
- Albers FC, et al. *Respir Res* 2019;20:169.
- Ortega HG, et al. *Ann Am Thorac Soc* 2014;11:1011–7.

Disclosures

- This analysis and the parent study (MEA112997; NCT01000506) were funded by GlaxoSmithKline (GSK).
- SWY and RGP are employees of GSK and hold stock/share options in GSK; JC receives research support from Sanofi; MC receives university grant funding from the NIH, American Lung Association, and Patient-Centered Outcomes Research Institute; receives pharmaceutical grant funding from AstraZeneca, GSK, Novartis, Pulmatrix, Sanofi-Aventis and Shionogi; serves as a

- consultant for AstraZeneca, Genentech, VIDA, Regeneron, Teva, and Sanofi-Aventis; serves as a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, and Teva; and receives royalties from Elsevier.
- Editorial support (in the form of writing assistance, assembling tables and figures, collating and incorporating author comments, grammatical editing, and referencing) was provided by Nathan Ley, PhD, at Fishawack Indicia Ltd, UK, and was funded by GSK.

A plain language summary and an online version of this poster can be accessed by scanning the QR code or via http://tago.ca/AAAAA_1

The plain language summary is also available at the GSK Medical Information booth

